by ImmonuoHorizons
Researchers have identified a promising new platform for preclinical testing of chimeric antigen receptor (CAR) T cell efficacy against solid tumors.
by Blood Advances
Early evidence supports a deeper look into candidate chimeric antigen receptor (CAR) T-cell therapies for the treatment of relapsed and refractory B-cell acute lymphoblastic leukemia (B-ALL) in...
by Alex Kadhim
Researchers at the Memorial Sloan Kettering Cancer Center reported two cases of patients with multiple myeloma (MM) and kidney failure who successfully underwent Chimeric Antigen Receptor (CAR)...
by BMC
The anti-tumor effects of CD19-targeted chimeric antigen receptor (CAR) T cells may potentially weaken following infusion due to immunogenicity of their antigen-recognition domains, but research...
by Alex Kadhim
In a collaborative study, researchers from the Dana-Farber Cancer Institute and Harvard Medical School, have developed a new strategy to enhance the activity and persistence of chimeric antigen...
by Science Immunology
With evidence showing that the scavenger receptor CD5 inhibits chimeric antigen receptor (CAR) T-cell activation, investigators believe that CD5 knockout is the key to improving the clinical...